CLEO Diagnostics Ltd (AU:COV) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
CLEO Diagnostics Ltd has announced the commencement of U.S. clinical trials for its novel ovarian cancer diagnostic blood test, with seven sites selected across various states, including Texas and New York. These trials, pivotal for obtaining FDA approval, are set to begin in mid-August 2024 and will be complemented by a concurrent trial in Australia. The company aims to address the critical need for early detection of ovarian cancer with its test, which distinguishes malignant from benign growths.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.